2017 American Transplant Congress » Concurrent Session: Kidney Immunosuppression: Induction Therapy

Date: Tuesday, May 2, 2017

Time: 2:30pm-4:00pm

Location: E354b

Session Type: Concurrent Session

Meeting: 2017 American Transplant Congress

2:30pm-2:42pm: Benefits of Induction in Recipients of Acute Renal Failure Donor Kidneys.

M. Barrett, A. Smith, K. Woodside, R. Sung.

2:42pm-2:54pm: Outcomes with Steroid Avoidance Regimen After Kidney Transplantation without Induction Immunosuppression.

A. Sakhuja,¹ A. Naik,² D. Cibrik,² H. Amer.³

2:54pm-3:06pm: Reassessing Thymoglobulin Induction in Kidney Transplantation (RETHINK): An Analysis of the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) Registry.

I. Ashoor,¹ K. Martz,² R. Beyl,³ V. Dharnidharka.⁴

3:06pm-3:18pm: Induction Therapy in Low Risk Elderly Kidney Transplant Recipients: Donor Factors.

F. Al Ammary, M. DeMarco, Q. Huang, E. King, S. Bay, A. Muzaale, A. Wiseman, D. Segev.

3:18pm-3:30pm: IVIg+Rituximab Desensitization (DES) Combined with Alemtuzumab (ATZ) Induction Does Not Increase Risk for Viral Infections (VIs) and Associated Complications in HLA-Sensitized (HS) Kidney Transplant Patients (KTx Pts).

S. Ge, B.-H. Shin, J. Mirocha, D. Thomas, M. Chu, E. Rodriguez, C. Chao, A. Petrosyan, O. Galera, A. Vo, J. Choi, A. Peng, J. Kahwaji, S. Jordan, M. Toyoda.

3:30pm-3:42pm: Five Year Outcomes with Alemtuzumab Induction Therapy in Elderly Renal Transplant Recipients.

M. Casagrande, K. Cunningham, C. Tseng, C. D'Agostino, L. Wong, C. Richardson.

3:42pm-3:54pm: Impact of Alemtuzumab Induction on Hepatitis C Treatment Outcomes Post-Renal Transplantation.

S. Jonchhe, J. Husson, J. Casale, R. Adekunle, P. Mathur, J. Gripshover, B. Ravichandran.

« View all sessions from the 2017 American Transplant Congress